RECRUITINGPhase 4INTERVENTIONAL
Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD
About This Trial
The study team will determine the association between d,l-methylphenidate (MPH) therapeutic outcomes in ADHD patients and genetic variants of CES1 and reveal key associations between CES1 genotypes and the PK and PD of MPH.
Who May Be Eligible (Plain English)
Who May Qualify:
\- Youth ages 6-17 years with ADHD as a primary diagnosis
Who Should NOT Join This Trial:
- Participants that do not have ADHD as a primary diagnosis
- Participants that do not want, require, or are not healthy enough for a single dose trial of MPH for ADHD per the clinical judgment of the treating and study clinicians
- Participants that are smokers or, are pregnant
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
\- Youth ages 6-17 years with ADHD as a primary diagnosis
Exclusion Criteria:
* Participants that do not have ADHD as a primary diagnosis
* Participants that do not want, require, or are not healthy enough for a single dose trial of MPH for ADHD per the clinical judgment of the treating and study clinicians
* Participants that are smokers or, are pregnant
Treatments Being Tested
DRUG
Methylphenidate
study to determine dose
Locations (4)
University of Florida
Gainesville, Florida, United States
Icahn School of Medicine at Mount Sinai
New York, New York, United States
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States
Seattle Children's Hospital
Seattle, Washington, United States